Perampanel during pregnancy: Description of four cases
Perampanel (PER) is approved in Italy as an adjunctive treatment for focal-onset seizures (FOS) and generalized tonic-clonic seizures (GTCs), and it could be an alternative to valproate in young women diagnosed with idiopathic generalized epilepsy. Nevertheless, clinical data about the outcome of pr...
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2021-01-01
|
| Series: | Epilepsy & Behavior Reports |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2589986421000642 |
| _version_ | 1818976546062336000 |
|---|---|
| author | A.M. Alicino G. Falcicchio G. Boero G. Santarcangelo T. Francavilla M. Trojano A. La Neve |
| author_facet | A.M. Alicino G. Falcicchio G. Boero G. Santarcangelo T. Francavilla M. Trojano A. La Neve |
| author_sort | A.M. Alicino |
| collection | DOAJ |
| description | Perampanel (PER) is approved in Italy as an adjunctive treatment for focal-onset seizures (FOS) and generalized tonic-clonic seizures (GTCs), and it could be an alternative to valproate in young women diagnosed with idiopathic generalized epilepsy. Nevertheless, clinical data about the outcome of pregnancies in women exposed to PER are lacking. Here, we report retrospectively collected data from four women suffering from FOS who were exposed to PER during pregnancy. Three pregnancies were carried out with PER as add-on therapy during the entire gestation (8 mg/day in two patients and 6 mg/day in one), without seizure frequency variations. The fourth patient started PER 2 mg/day as monotherapy during the 13th week of pregnancy due to seizure relapse and continued it until delivery with complete seizure control. All pregnancies showed good outcomes, and their newborns did not possess major congenital malformations. Apgar scores and auxological parameters at birth were normal. Fetal pathology in follow-up during pregnancies was absent in all cases. In our patients PER was well tolerated and appeared safe for the fetuses and did not result in major malformations or adverse events at birth. Nevertheless, this is a report involving a small number of patients and it does not suggest the general use of PER is safe during pregnancy. |
| first_indexed | 2024-12-20T16:13:34Z |
| format | Article |
| id | doaj.art-cd817a553ce646ed9b1b721254bc4acb |
| institution | Directory Open Access Journal |
| issn | 2589-9864 |
| language | English |
| last_indexed | 2024-12-20T16:13:34Z |
| publishDate | 2021-01-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Epilepsy & Behavior Reports |
| spelling | doaj.art-cd817a553ce646ed9b1b721254bc4acb2022-12-21T19:33:54ZengElsevierEpilepsy & Behavior Reports2589-98642021-01-0116100490Perampanel during pregnancy: Description of four casesA.M. Alicino0G. Falcicchio1G. Boero2G. Santarcangelo3T. Francavilla4M. Trojano5A. La Neve6Department of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, ItalyDepartment of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, ItalyComplex Structure of Neurology, SS Annunziata Hospital, Taranto, Italy; Corresponding author at: Via Francesco Bruno 1, Taranto 74121, Italy.Territorial Neurology Service, Policoro, ASM Matera, ItalyDepartment of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, ItalyDepartment of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, ItalyDepartment of Basic Medical Sciences, Neurosciences and Sense Organs, University of Bari, Bari, ItalyPerampanel (PER) is approved in Italy as an adjunctive treatment for focal-onset seizures (FOS) and generalized tonic-clonic seizures (GTCs), and it could be an alternative to valproate in young women diagnosed with idiopathic generalized epilepsy. Nevertheless, clinical data about the outcome of pregnancies in women exposed to PER are lacking. Here, we report retrospectively collected data from four women suffering from FOS who were exposed to PER during pregnancy. Three pregnancies were carried out with PER as add-on therapy during the entire gestation (8 mg/day in two patients and 6 mg/day in one), without seizure frequency variations. The fourth patient started PER 2 mg/day as monotherapy during the 13th week of pregnancy due to seizure relapse and continued it until delivery with complete seizure control. All pregnancies showed good outcomes, and their newborns did not possess major congenital malformations. Apgar scores and auxological parameters at birth were normal. Fetal pathology in follow-up during pregnancies was absent in all cases. In our patients PER was well tolerated and appeared safe for the fetuses and did not result in major malformations or adverse events at birth. Nevertheless, this is a report involving a small number of patients and it does not suggest the general use of PER is safe during pregnancy.http://www.sciencedirect.com/science/article/pii/S2589986421000642EpilepsyPerampanelPregnancyAnti-seizure medications (ASMs)Neonatal major malformations |
| spellingShingle | A.M. Alicino G. Falcicchio G. Boero G. Santarcangelo T. Francavilla M. Trojano A. La Neve Perampanel during pregnancy: Description of four cases Epilepsy & Behavior Reports Epilepsy Perampanel Pregnancy Anti-seizure medications (ASMs) Neonatal major malformations |
| title | Perampanel during pregnancy: Description of four cases |
| title_full | Perampanel during pregnancy: Description of four cases |
| title_fullStr | Perampanel during pregnancy: Description of four cases |
| title_full_unstemmed | Perampanel during pregnancy: Description of four cases |
| title_short | Perampanel during pregnancy: Description of four cases |
| title_sort | perampanel during pregnancy description of four cases |
| topic | Epilepsy Perampanel Pregnancy Anti-seizure medications (ASMs) Neonatal major malformations |
| url | http://www.sciencedirect.com/science/article/pii/S2589986421000642 |
| work_keys_str_mv | AT amalicino perampanelduringpregnancydescriptionoffourcases AT gfalcicchio perampanelduringpregnancydescriptionoffourcases AT gboero perampanelduringpregnancydescriptionoffourcases AT gsantarcangelo perampanelduringpregnancydescriptionoffourcases AT tfrancavilla perampanelduringpregnancydescriptionoffourcases AT mtrojano perampanelduringpregnancydescriptionoffourcases AT alaneve perampanelduringpregnancydescriptionoffourcases |